Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management
Public ClinicalTrials.gov record NCT05243511. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
"PROSPER-FM": Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management
Study identification
- NCT ID
- NCT05243511
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Swing Therapeutics, Inc.
- Other
- Enrollment
- 275 participants
Conditions and interventions
Conditions
Interventions
- Digital ACT Device
- Digital Symptom Tracker Other
Device · Other
Eligibility (public fields only)
- Age range
- 22 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 7, 2022
- Primary completion
- May 14, 2023
- Completion
- May 14, 2023
- Last update posted
- Jun 14, 2023
2022 – 2023
United States locations
- U.S. sites
- 25
- U.S. states
- 12
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site #37 | Covina | California | 91722 | — |
| Site #15 | Oceanside | California | 92056 | — |
| Site #31 | San Bernardino | California | 92498 | — |
| Site #38 | Thousand Oaks | California | 91360 | — |
| Site #36 | Tujunga | California | 91042 | — |
| Site #35 | Whittier | California | 90602 | — |
| Site #13 | Orlando | Florida | 32801 | — |
| Site #33 | St. Petersburg | Florida | 33709 | — |
| Site #25 | Atlanta | Georgia | 30329 | — |
| Site #21 | Covington | Louisiana | 70433 | — |
| Site #20 | New Orleans | Louisiana | 70124 | — |
| Site #22 | Prairieville | Louisiana | 70769 | — |
| Site #39 | Chestnut Hill | Massachusetts | 02467 | — |
| Site #24 | Ocean Springs | Mississippi | 39564 | — |
| Site #34 | Brooklyn | New York | 11235 | — |
| Site #32 | Scarsdale | New York | 10583 | — |
| Site #12 | Williamsville | New York | 14221 | — |
| Site #27 | Fargo | North Dakota | 58104 | — |
| Site #14 | Cincinnati | Ohio | 45219 | — |
| Site #28 | Dayton | Ohio | 45419 | — |
| Site #23 | Tulsa | Oklahoma | 74133 | — |
| Site #16 | Allentown | Pennsylvania | 18104 | — |
| Site #29 | Austin | Texas | 78726 | — |
| Site #26 | McKinney | Texas | 75070 | — |
| Site #30 | Pflugerville | Texas | 78660 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05243511, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 14, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05243511 live on ClinicalTrials.gov.